All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
149 results for "Cancer"
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Protocol No
MERCK-MK-7339-010
Sub Category
Prostate and Urologic Cancers
A Phase II Study Of Medi4736 (Durvalumab) Plus Tremelimumab As Therapy For Patients With Previously Treated Anti-Pd-1/Pd-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Protocol No
SWOG-S1400F
Sub Category
Thoracic Cancers
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients (18- <70 yrs) with CLL
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
Protocol No
ECOG-EA9161
Sub Category
Hematologic/Blood Related Cancers
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Durvalumab Following SBRT for the Treatment of Patients with Stage I/II NSCLC
Protocol No
AZ-D9103C00001-PACIFIC-4
Sub Category
Thoracic Cancers
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients 65 Years of Age and Up with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients 65 Years of Age and Up with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/refractory) with Known or Presumed Activating
Blinatumomab and either POMP or Dasatinib and Prednisone in Patients >/= 65 With Newly Diagnosed ALL.
Protocol No
SWOG-S1318
Sub Category
Hematologic/Blood Related Cancers
Phase II Randomized Trial Of Neo-Adjuvant Chemotherapy Followed By Surgery And Post-Operative Radiation Versus Surgery And Post-Operative Radiation For Organ Preservation Of T3 And T4a Nasal And Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area
Protocol No
ECOG-EA3163
Sub Category
Head and Neck Cancers
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide in mCRPC
Protocol No
MERCK-MK-3475-641
Sub Category
Prostate and Urologic Cancers
A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-stage, P16-positive, Non-smoking Associated Oropharyngeal Cancer
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Protocol No
NRG-HN005
Sub Category
Head and Neck Cancers
Phase 1 Safety Study of Descartes-11 in Patients with Relapsed Refractory Myeloma
Descartes-11 in relapse/refractory MM
Protocol No
CARTESIAN-DESCARTES-11-RRMM
Sub Category
Hematologic/Blood Related Cancers
A Phase Ib/II, Open-label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with CHOP or CHP-Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Protocol No
HOFFMANN-LAROCHE-GO40515
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Protocol No
FORMA-2102-ONC-102
Sub Category
Brain and Spine Cancers
Early Phase/Multiple Disease Site Cancers
Sarcoma
Gastrointestinal Cancers
A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients with Advanced Solid Tumors
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Protocol No
SANOFI-TED13751
Sub Category
Thoracic Cancers
Early Phase/Multiple Disease Site Cancers
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol No
TENEOBIO-TNB-383B
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
A Phase I/II study to investigate the safety and clinical activity of GSK3326595 and other agents in subjects with myelodysplastic syndrome and acute myeloid leukaemia.
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML)
Protocol No
GSK-208809
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Protocol No
GENENTECH-MYPATHWAY
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers